{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:20Z","timestamp":1793039900680,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001658","name":"Minerva Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005634","name":"Suomen Hammasl\u00e4\u00e4k\u00e4riseura Apollonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Immune checkpoint inhibitors (ICIs), primarily anti-PD-1, are currently used to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, only a minority of patients benefit from these costly therapies. Therefore, there is an unmet need to better understand the effect of ICIs on immune effector cells. This study aimed to investigate the effect of a PD-1 antibody and an IDO1 inhibitor on different lymphocyte populations (NK, CD4\n                      <jats:sup>+<\/jats:sup>\n                      , and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells) in term of migration, cytotoxicity, and cytokine release in the presence of HNSCC cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using a microfluidic chip, we injected HSC-3 cells (an oral tongue squamous cell carcinoma cell line) embedded in a human tumor-derived matrix \u201cmyogel\/fibrin\u201d together with NK, CD4\n                      <jats:sup>+<\/jats:sup>\n                      , and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in separate channels. The two channels were connected with microchannels. The PD-1 antibody nivolumab and IDO1 inhibitor epacadostat were added to the microfluidic chips. Lymphocyte migration and cytotoxicity were examined under fluorescent microscopy and cytokine release was measured using a FirePlex Human Discovery Cytokines Immunoassay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Epacadostat significantly increased the migration and infiltration of NK and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells, but not CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, towards the cancer cells. Nivolumab did not exhibit a similar effect. While CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells alone showed near to no migration, adding CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells enhanced migration towards the cancer cells. There was a mild nonsignificant increase in apoptosis of HSC-3 cells after adding epacadostat to lymphocytes. In contrast, HSC-3 proliferation was not affected by lymphocytes regardless of ICIs. Nivolumab significantly increased release of MIP1-\u03b1, IL-6, and IL-8 from NK, CD4\n                      <jats:sup>+<\/jats:sup>\n                      , and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study revealed that each subpopulation of lymphocytes respond differently to ICIs. We also revealed the subpopulation of lymphocytes responsible for the increases in specific serum cytokines after ICI treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.812822","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T01:30:05Z","timestamp":1647221405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Meri","family":"Sievil\u00e4inen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Saavalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady","family":"Adnan-Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1038\/s41598-020-64748-0","article-title":"Increasing Incidence and Improving Survival of Oral Tongue Squamous Cell Carcinoma","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and Neck Squamous Cell Carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00052","article-title":"Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy","volume":"7","author":"Canning","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707975","article-title":"Recent Advances in Head and Neck Cancer","volume":"359","author":"Haddad","year":"2008","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0963","article-title":"Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"33","author":"Sacco","year":"2015","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41368-020-0084-8","article-title":"Immune Checkpoint Pathways in Immunotherapy for Head and Neck Squamous Cell Carcinoma","volume":"12","author":"Mei","year":"2020","journal-title":"Int J Oral Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00563","article-title":"Progresses and Perspectives of Anti-PD-1\/PD-L1 Antibody Therapy in Head and Neck Cancers","volume":"8","author":"Yang","year":"2018","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102966","article-title":"Immunotherapy Improves Efficacy and Safety of Patients With HPV Positive and Negative Head and Neck Cancer: A Systematic Review and Meta-Analysis","volume":"150","author":"Galvis","year":"2020","journal-title":"Crit Rev Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061413","article-title":"Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study","volume":"13","author":"Vasiliadou","year":"2021","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune Control by Amino Acid Catabolism During Tumorigenesis and Therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/coa.13794","article-title":"The Immunotherapeutic Role of Indoleamine 2, 3-Dioxygenase in Head and Neck Squamous Cell Carcinoma: A Systematic Review","volume":"46","author":"Lin","year":"2021","journal-title":"Clin Otolaryngol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111508","article-title":"In Vitro Humanized 3D Microfluidic Chip for Testing Personalized Immunotherapeutics for Head and Neck Cancer Patients","volume":"383","author":"Al-Samadi","year":"2019","journal-title":"Exp Cell Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.024","article-title":"Combining Type I Interferons and 5-Aza-2\u2032-Deoxycitidine to Improve Anti-Tumor Response Against Melanoma","volume":"137","author":"Lucarini","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2306-1","article-title":"In Vitro Assessment of Anti-Tumor Potential and Combination Effect of Classical and Molecular-Targeted Anticancer Drugs","volume":"39","author":"Iijima","year":"2019","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I\/II Trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1944-z","article-title":"A Novel Human Leiomyoma Tissue Derived Matrix for Cell Culture Studies","volume":"15","author":"Salo","year":"2015","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17768","article-title":"Cross-Talk Between Tongue Carcinoma Cells, Extracellular Vesicles, and Immune Cells in In Vitro and In Vivo Models","volume":"8","author":"Al-Samadi","year":"2017","journal-title":"Oncotarget"},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdy507","article-title":"Immune Biomarkers of Response to Immune-Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma","volume":"30","author":"Oliva","year":"2019","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of Resistance to Immune Checkpoint Inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","article-title":"Turning Cold Tumors Into Hot Tumors by Improving T-Cell Infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00382","article-title":"Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients","volume":"8","author":"Mazorra","year":"2017","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1039\/D0LC01305F","article-title":"Microfluidic Technologies for Immunotherapy Studies on Solid Tumours","volume":"12","author":"Paterson","year":"2021","journal-title":"Lab Chip"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in Clinical Cancer Immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155363","article-title":"Potential Predictive Value of Change in Inflammatory Cytokines Levels Subsequent to Initiation of Immune Checkpoint Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer","volume":"138","author":"Lim","year":"2021","journal-title":"Cytokine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000678","article-title":"Plasma IL-6 Changes Correlate to PD-1 Inhibitor Responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum Interleukin-6 and C-Reactive Protein Are Associated With Survival in Melanoma Patients Receiving Immune Checkpoint Inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in Serum Interleukin-8 (IL-8) Levels Reflect and Predict Response to Anti-PD-1 Treatment in Melanoma and Non-Small-Cell Lung Cancer Patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/or.18.5.1107","article-title":"Dual Role of CCL3\/CCR1 in Oral Squamous Cell Carcinoma: Implications in Tumor Metastasis and Local Host Defense","volume":"18","author":"Silva","year":"2007","journal-title":"Oncol Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2306-1","article-title":"Serum CCL2 and CCL3 as Potential Biomarkers for the Diagnosis of Oral Squamous Cell Carcinoma","volume":"35","author":"Ding","year":"2014","journal-title":"Tumor Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.290","article-title":"CTL-vs T Reg Lymphocyte-Attracting Chemokines, CCL4 and CCL20, Are Strong Reciprocal Predictive Markers for Survival of Patients With Oesophageal Squamous Cell Carcinoma","volume":"113","author":"Liu","year":"2015","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.V104.11.5268.5268","article-title":"Intratumoral Expression of MIP-1beta Induces Anti-Tumor Responses in a Pre-Established Tumor Model Through Chemoattracting T Cells and NK Cells","volume":"1","author":"Luo","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ijom.2017.09.016","article-title":"Evaluation of Saliva and Plasma Cytokine Biomarkers in Patients With Oral Squamous Cell Carcinoma","volume":"47","author":"Lee","year":"2018","journal-title":"Int J Oral Maxillofac Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/1010428318810059","article-title":"The Relationship Between Chemokines CCL2, CCL3, and CCL4 With the Tumor Microenvironment and Tumor-Associated Macrophage Markers in Colorectal Cancer","volume":"40","author":"De la Fuente L\u00f3pez","year":"2018","journal-title":"Tumor Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12643","article-title":"High Levels of CCL2 or CCL4 in the Tumor Microenvironment Predict Unfavorable Survival in Lung Adenocarcinoma","volume":"9","author":"Li","year":"2018","journal-title":"Thorac Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01769","article-title":"Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report","volume":"9","author":"Merhi","year":"2018","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088952","article-title":"Monocyte Chemotactic Protein 1 (MCP-1) Modulates Pro-Survival Signaling to Promote Progression of Head and Neck Squamous Cell Carcinoma","volume":"9","author":"Ji","year":"2014","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu046","article-title":"A CCL2\/ROS Autoregulation Loop Is Critical for Cancer-Associated Fibroblasts-Enhanced Tumor Growth of Oral Squamous Cell Carcinoma","volume":"35","author":"Li","year":"2014","journal-title":"Carcinogenesis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.5.3332","article-title":"Tumor-Derived Chemokine MCP-1\/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells","volume":"179","author":"Brown","year":"2007","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.135","article-title":"The Chemokine MCP-1 (CCL2) in the Host Interaction With Cancer: A Foe or Ally","volume":"15","author":"Yoshimura","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.100","article-title":"Serum IL-6 and CRP as Prognostic Factors in Melanoma Patients Receiving Single Agent and Combination Checkpoint Inhibition","volume":"37","author":"Weber","year":"2019","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0860-1","article-title":"High Systemic and Tumor-Associated IL-8 Correlates With Reduced Clinical Benefit of PD-L1 Blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.wjorl.2016.05.002","article-title":"Interleukin-6 Role in Head and Neck Squamous Cell Carcinoma Progression","volume":"2","author":"Choudhary","year":"2016","journal-title":"World J Otorhinolaryngol Head Neck Sug"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2004.06.005","article-title":"Serum Concentrations of Interleukin-8, Vascular Endothelial Growth Factor, and Epidermal Growth Factor Receptor in Patients With Squamous Cell Cancer of the Head and Neck","volume":"41","author":"Gokhale","year":"2005","journal-title":"Oral Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12670","article-title":"Proinflammatory Cytokines as Serum Biomarker in Oral Carcinoma\u2014A Prospective Multi-Biomarker Approach","volume":"47","author":"Schiegnitz","year":"2018","journal-title":"J Oral Pathol Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.155347752","article-title":"Evaluating Natural Killer Cell Cytotoxicity Against Solid Tumors Using a Microfluidic Model","volume":"8","author":"Ayuso","year":"2019","journal-title":"OncoImmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.812822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T01:30:11Z","timestamp":1647221411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.812822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2022.812822"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.812822","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"article-number":"812822"}}